"bcl-X Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the bcl-2 protein family that plays a role in the regulation of APOPTOSIS and is a regulatory subunit for PROTEIN PHOSPHATASE 1. Two major isoforms of the protein exist due to ALTERNATIVE SPLICING of the BCL2L1 mRNA and are referred to as Bcl-XS and Bcl-XL.
| Descriptor ID |
D051020
|
| MeSH Number(s) |
D12.644.360.075.718.937 D12.776.476.075.718.875
|
| Concept/Terms |
bcl-X Protein- bcl-X Protein
- bcl X Protein
- bcl2-Like 1 Protein
- bcl2 Like 1 Protein
- bcl2L1 Protein
bcl-XS Protein- bcl-XS Protein
- bcl XS Protein
- bcl-Xshort Protein
- bcl Xshort Protein
- bcl-X(S) Protein
bcl-Xbeta Protein- bcl-Xbeta Protein
- bcl Xbeta Protein
- bcl-Xb Protein
- bcl Xb Protein
- bcl-x(beta) Protein
bcl-XL Protein- bcl-XL Protein
- bcl XL Protein
- bcl-Xlong Protein
- bcl Xlong Protein
- bcl-X(L) Protein
|
Below are MeSH descriptors whose meaning is more general than "bcl-X Protein".
Below are MeSH descriptors whose meaning is more specific than "bcl-X Protein".
This graph shows the total number of publications written about "bcl-X Protein" by people in this website by year, and whether "bcl-X Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 5 | 5 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 8 | 8 |
| 2002 | 0 | 7 | 7 |
| 2003 | 0 | 10 | 10 |
| 2004 | 0 | 12 | 12 |
| 2005 | 4 | 6 | 10 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 7 | 8 |
| 2008 | 0 | 5 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 6 | 8 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 6 | 6 |
| 2015 | 1 | 4 | 5 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 2 | 1 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "bcl-X Protein" by people in Profiles.
-
Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy. Life Sci Alliance. 2024 04; 7(4).
-
BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs. Cancer Res. 2023 11 01; 83(21):3501-3503.
-
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. 2023 10 01; 108(10):2626-2638.
-
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023 03 30; 141(13):1610-1625.
-
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021 11 25; 12(1):6896.
-
BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. Theranostics. 2021; 11(19):9180-9197.
-
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells. 2021 04 06; 10(4).
-
Bcl-2-Protein Family as Modulators of IP3 Receptors and Other Organellar Ca2+ Channels. Cold Spring Harb Perspect Biol. 2020 04 01; 12(4).
-
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 12; 25(12):1938-1947.
-
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol Cancer Ther. 2019 03; 18(3):642-655.